چهارشنبه 3 تیر 1405
[Archive]
پذیرفته شده و در حال انتشار
برگشت به فهرست مقالات |
برگشت به فهرست نسخه ها
چکیده: (7 مشاهده)
Background and Objectives: This randomized, double-blind, placebo-controlled clinical trial investigates the efficacy of Taryaqe Vabaei, a traditional herbal formulation consisting of Aloe barbadensis, Commiphora myrrh, and Crocus sativus, in alleviating Upper respiratory tract infections (URTIs) symptoms.
Materials and methods: Sixty-six participants aged 25–60 with mild URTI symptoms were randomized into two groups. The intervention group received 500 mg of Taryaqe Vabaei twice daily for 14 days, while the control group received a placebo. Symptom severity was the primary outcome. For normally distributed data, independent and paired t-tests were used; for non-normally distributed data, the Mann-Whitney U and Wilcoxon signed-rank tests were applied. Categorical variables were analyzed using the chi-square test (SPSS v.26, significance at P<0.05).
Results: The intervention group showed significantly faster recovery times for body pain (0.85±1.23 vs. 4.36±1.82 days, p<0.001), sore throat (p<0.001), runny nose (p<0.001), cough (p<0.001), sneezing (p<0.001), fever (p<0.001), and confusion (0.71±1.43 vs. 0.06±0.36 days, p=0.01). Symptom severity decreased by 40% after one week in the intervention group, with significant improvements in overall symptom scores compared to placebo.
Conclusion: Although Taryaqe Vabaei showed promising results in reducing URTI symptoms, larger, longer-term studies are required to confirm its efficacy, explore safety profiles, and assess potential interactions with conventional treatments. These findings highlight the potential of Taryaqe Vabaei as an effective complementary therapy for managing URTIs.
Materials and methods: Sixty-six participants aged 25–60 with mild URTI symptoms were randomized into two groups. The intervention group received 500 mg of Taryaqe Vabaei twice daily for 14 days, while the control group received a placebo. Symptom severity was the primary outcome. For normally distributed data, independent and paired t-tests were used; for non-normally distributed data, the Mann-Whitney U and Wilcoxon signed-rank tests were applied. Categorical variables were analyzed using the chi-square test (SPSS v.26, significance at P<0.05).
Results: The intervention group showed significantly faster recovery times for body pain (0.85±1.23 vs. 4.36±1.82 days, p<0.001), sore throat (p<0.001), runny nose (p<0.001), cough (p<0.001), sneezing (p<0.001), fever (p<0.001), and confusion (0.71±1.43 vs. 0.06±0.36 days, p=0.01). Symptom severity decreased by 40% after one week in the intervention group, with significant improvements in overall symptom scores compared to placebo.
Conclusion: Although Taryaqe Vabaei showed promising results in reducing URTI symptoms, larger, longer-term studies are required to confirm its efficacy, explore safety profiles, and assess potential interactions with conventional treatments. These findings highlight the potential of Taryaqe Vabaei as an effective complementary therapy for managing URTIs.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
